Potential roles of RNA N6-methyladenosine (m6A) modification in tumour microenvironment (TME) cell infiltration has been demonstrated in recent studies. Nonetheless, the mechanism of its regulation remains unknown and immunotherapy has been marginal in prostate cancer. We demonstrated the expression of different m6A regulators within prostate cancer related to genetic variation, alternative splicing (AS), tumour mutational burden (TMB) and TME. Unsupervised clustering and risk prediction model constructed by 24 m6A regulators could predict scores of TME and prostate cancer patients prognosis. T cells CD8 was the intersection of immune cells which are related to multiple biological processes, and the fraction of T cells CD8 strongly correlates with immune associated gene sets. m6A methylation modification and immune cells infiltration played a nonnegligible role in prostate cancer. Our study represents a step towards personalized immunotherapy for prostate cancer patients.

中文翻译：

---

前列腺癌中 RNA m6A 甲基化调节因子和肿瘤免疫细胞浸润特征的分析。


最近的研究已经证明了 RNA N6-甲基腺苷 (m6A) 修饰在肿瘤微环境 (TME) 细胞浸润中的潜在作用。尽管如此，其调节机制仍不清楚，免疫疗法在前列腺癌中一直处于边缘地位。我们证明了前列腺癌中不同 m6A 调节因子的表达与遗传变异、选择性剪接 (AS)、肿瘤突变负荷 (TMB) 和 TME 相关。由 24 个 m6A 调节器构建的无监督聚类和风险预测模型可以预测 TME 评分和前列腺癌患者预后。 T细胞CD8是与多种生物过程相关的免疫细胞的交集，T细胞CD8的比例与免疫相关基因集密切相关。 m6A甲基化修饰和免疫细胞浸润在前列腺癌中发挥着不可忽视的作用。我们的研究代表了前列腺癌患者个性化免疫治疗的一步。